Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

13q deletions in lymphoid malignancies

Y Liu1, M Hermanson, D Grandér

  • 1Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.

Blood
|September 1, 1995
PubMed
Summary

13q14 deletions are common in lymphoid cancers like B-cell chronic lymphocytic leukemia (B-CLL) and non-Hodgkin's lymphoma (NHL). Deletion of the D13S319 marker suggests a tumor suppressor gene critical for these diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Namibian spitting cobra, Naja nigricincta nigricincta (Zebra snake): Antibiotic profile of bacteria cultured from the oral pharynx, venom and snakebite wounds.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2023
Same author

Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death.

Science advances·2020
Same author

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.

Leukemia·2017
Same author

A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia.

Leukemia & lymphoma·2016
Same author

Cytogenetic Findings and Survival in B-cell Chronic Lymphocytic Leukemia. Second IWCCLL Compilation of Data on 662 Patients.

Leukemia & lymphoma·2016
Same author

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

Leukemia·2016

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • A candidate tumor suppressor gene is located at 13q14, a region frequently deleted in B-cell chronic lymphocytic leukemia (B-CLL).
  • Understanding the frequency and precise location of 13q deletions in lymphoid neoplasms is crucial for identifying this gene.

Purpose of the Study:

  • To determine the frequency and minimal region of overlap for 13q deletions in various lymphoid malignancies.
  • To investigate the role of specific markers, such as D13S319, in the deletion process.

Main Methods:

  • Analysis of 13q deletions in malignant cells from B-cell chronic lymphocytic leukemia (B-CLL), non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), and T-cell lines.
  • Utilized genetic markers including D13S319, RBkpt, and D13S25 to define deletion regions.

Related Experiment Videos

Main Results:

  • 13q14 deletions were observed in 44% of B-CLL, 25% of NHL, and 28% of ALL cases.
  • The D13S319 marker was the most frequently deleted in B-CLL and NHL.
  • Homozygous deletions of D13S319 were found in 10 B-CLL cases, with six cases showing deletions solely at this locus.

Conclusions:

  • 13q deletions are a common event in lymphoid neoplasms.
  • The deletion of a candidate tumor suppressor gene near the D13S319 marker is implicated in the development of these cancers.
  • RB1 gene inactivation may be significant in some acute lymphocytic leukemia cases with 13q deletions.